Epithalon (also called Epitalon or Epithalone) occupies a unique position in the peptide landscape: it has a plausible mechanism shown at the cellular level, decades of animal work, and essentially no large-scale human clinical trials. This creates a situation where the dosing protocol is well-established within the longevity medicine community but is derived primarily from the research of one group — Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology — rather than from internationally replicated dose-finding studies. A 2026 independent review found no adequately powered randomised human trial and no adequate dose-ranging or long-term safety data (Jain et al., 2026).
Let me be direct about what we know and where the gaps are.
At a Glance
| Property | Value |
|---|---|
| What it is | Synthetic tetrapeptide (Ala-Glu-Asp-Gly) modelled on epithalamin, a pineal gland extract |
| Evidence Level | Emerging (cell-culture and rodent data; no adequately powered human trial) |
| Standard Dose | Community courses: 5-10 mg subcutaneously, daily (anecdotal). Published human studies: 10 mcg IM or 0.5 mg sublingual daily |
| Cycle Length | 10-20 days |
| Frequency | 2-3 courses per year in community reports |
| Key Mechanism | Telomerase activation, telomere elongation |
| Route | Subcutaneous injection (preferred); IV (clinical research) |
| Monitoring | Telomere length testing before and after |
| Lifespan data | Mice: no change in average lifespan; longer survival in the longest-lived 10% (Anisimov et al., 2003) |
| Approval status | Not approved by the FDA, EMA or BfArM |
| Anti-doping (WADA 2026) | Prohibited at all times as a non-approved substance (S0) |
Protocol Table: Dose, Route, Timing and Basis
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
One row per use case. Basis: Trial (published human study, PMID), Practice protocol (reported by at least two independent compilations), Anecdotal (community reports only). Read the first two rows next to the third: the published human studies of synthetic epitalon used doses hundreds of times lower than the most common community course.
| Goal | Dose | Route | Frequency / timing | Cycle length | Basis |
|---|---|---|---|---|---|
| Melatonin rhythm in older adults | 10 mcg (0.01 mg) | IM | Once daily | 10 days | Trial (small study, 15 people on epitalon; dose as tabulated in Jain 2026; original PMID 17969590) |
| Low melatonin production in night-shift workers | 0.5 mg | Sublingual | Once daily | 20 days | Trial (20 on epitalon, 20 placebo; biomarker endpoints only; PMID 33280326) |
| Anti-ageing course, most reported community protocol | 5 mg | SC, evening | Once daily | 20 days, repeated 2-3 times a year | Anecdotal (Peptide Protocol Wiki, the most common protocol in 90 reports) |
| Telomere-focused, higher dose | 5-10 mg (most sources cap at 10 mg a day) | SC | Once daily | 10-20 days, 2-3 times a year | Anecdotal (Peptide Protocol Wiki) |
| Low-dose course | 100-500 mcg (300 mcg described as the “Russian clinical equivalent”) | SC | Once daily | 10-20 days, 4-6 months between courses | Anecdotal (Peptide DB) |
| Oral or sublingual | 5-10 mg | Oral | Once daily | 10-30 days | Anecdotal (Peptide Protocol Wiki, niche) |
| Intranasal | 1-5 mg | Intranasal | Once daily | 10-20 days | Anecdotal (Peptide Protocol Wiki, niche) |
| Combined with thymalin (Khavinson pairing) | Epitalon course as above + thymalin course | SC or IM | Once daily | 10-20 days | Anecdotal (Peptide Protocol Wiki) |
The 5-10 mg community course is often called the Khavinson protocol, but the human studies of epitalon summarised in the 2026 review used 10 mcg intramuscularly or 0.5 mg under the tongue, and the larger long-term human studies used epithalamin, the pineal extract, at 10 mg intramuscularly (Jain 2026). Peptide DB argues that the milligram doses may stem from translation errors of Russian protocols; nobody has tested the community dose in a published human study.
Technique, reconstitution and storage are in the peptide injection guide.
What Epithalon Is and What It Does
Telomeres are protective caps at the ends of chromosomes. They shorten with each cell division, and short telomeres are associated with ageing and some age-related diseases. The enzyme telomerase can rebuild them. Most adult body cells keep telomerase switched off, which is one of the brakes on uncontrolled cell division.
Epithalon was synthesised by Vladimir Khavinson’s group in St. Petersburg, based on the amino-acid composition of epithalamin, a polypeptide extract from the pineal gland. The two are chemically different, and studies of one do not automatically apply to the other (Jain et al., 2026).
In human fetal fibroblast cultures, adding epithalon switched on telomerase and lengthened telomeres (Khavinson et al., 2003). A 2025 study from a different group confirmed telomere lengthening in normal human cells in culture. It also found that epithalon lengthened telomeres in two breast cancer cell lines, through a telomerase-independent route known as ALT (alternative lengthening of telomeres) (Al-Dulaimi et al., 2025).
Epithalon Dosage: The So-Called Khavinson Protocol
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
The course structure (short daily courses repeated during the year) comes from the work of Vladimir Khavinson and colleagues, who have published on pineal gland peptides and bioregulation for four decades. The milligram dose does not: the human studies of synthetic epitalon used 10 mcg a day intramuscularly or 0.5 mg a day under the tongue (Jain et al., 2026).
The Standard Community Protocol
| Parameter | Protocol |
|---|---|
| Dose | 5-10 mg per day (Anecdotal; community reports, not a trial dose) |
| Route | Subcutaneous injection |
| Frequency | Once daily, typically evening |
| Duration | 10 days (standard) to 20 days (extended) |
| Courses per year | 2-3, spaced about 4-6 months apart (Anecdotal) |
| Best time of day | Evening (aligns with melatonin synthesis cycle) |
Where This Protocol Comes From
The 10-20 day course, repeated two or three times a year, is the most reported pattern in community use. The structure echoes Khavinson’s research: the developing group administered its pineal peptides in repeated short courses in animal studies (Anisimov & Khavinson, 2010) and in its older human work with the pineal extract epithalamin (Khavinson & Morozov, 2003). The milligram range was not established in a human dose-finding study (Jain et al., 2026); it is the range used in practice. The pharmacokinetic rationale is that telomerase activation does not require continuous peptide presence — the enzyme, once activated, continues its work during the rest period.
Pharmacokinetic Rationale for Cycling
The cycling schedule is not arbitrary. The logic is:
-
Telomerase activation is a trigger, not a sustained process. Epithalon activates the TERT gene (telomerase reverse transcriptase), which produces telomerase enzyme. Once the gene is expressed, the enzyme operates independently of ongoing Epithalon presence.
-
Telomere elongation is slow. Adding measurable telomere length takes weeks to months. A 10-day course initiates the process; the cellular effects continue long after the peptide is cleared.
-
Assessment window. By spacing courses 4-6 months apart, you create a natural assessment window — measure telomere length before each course to evaluate whether the previous course had a measurable effect.
-
Precautionary principle. Continuous telomerase activation raises theoretical concerns about enabling abnormal cell proliferation. Intermittent dosing is considered safer, though this specific risk has not been demonstrated with Epithalon in any published study.
What the Evidence Shows
Preclinical
| Study | Model | What was studied | Finding | Certainty |
|---|---|---|---|---|
| Khavinson et al., 2003 | Human fetal fibroblasts (cell culture) | Telomerase activity and telomere length | Telomerase switched on, telomeres lengthened | Low (single lab, cell culture) |
| Al-Dulaimi et al., 2025 | Normal human cells and breast cancer cell lines | Telomere length, hTERT, ALT activity | Lengthening in normal cells via telomerase; in cancer cells via ALT | Low (cell culture) |
| Anisimov et al., 2003 | Female SHR mice, lifelong monthly injections, 54 per group | Lifespan, ageing biomarkers, tumours | No change in average lifespan; last 10% of survivors lived 13% longer; fewer leukaemias; total tumour incidence unchanged | Low (one strain, one lab) |
The developing group’s broader review reports longer life and fewer tumours in rodents with several of its peptides (Anisimov & Khavinson, 2010). Independent replication of the lifespan findings is lacking.
Human
The most quoted human study followed 266 older people in Russia and Ukraine for six to eight years, some of whom received the pineal extract epithalamin and the thymus extract thymalin for the first two to three years. The authors reported fewer respiratory infections, less cardiovascular disease and lower mortality in treated groups (Khavinson & Morozov, 2003). This study tested extracts, not synthetic epithalon. It was run by the developers, and its design does not meet the standards of a modern randomised controlled trial. An independent 2026 review concluded that human evidence for synthetic epithalon is limited to small physiological or biomarker studies and that pharmacokinetic, dose-ranging and long-term safety data remain inadequate (Jain et al., 2026).
For how this compares with better-studied longevity approaches, see Epithalon vs NMN.
Practical Dosing Protocol
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
The three tiers below follow the community courses in the protocol table above (basis: Anecdotal). None of these milligram doses has been tested in a published human study.
Beginner Epithalon Protocol (Conservative)
| Parameter | Recommendation |
|---|---|
| Dose | 5 mg subcutaneously, daily |
| Duration | 10 days |
| Timing | Evening (6-9 PM) |
| Courses per year | 1 |
| Monitoring | Telomere length at baseline and 3 months post-course |
Standard Epithalon Protocol
| Parameter | Recommendation |
|---|---|
| Dose | 10 mg subcutaneously, daily |
| Duration | 10 days |
| Timing | Evening (6-9 PM) |
| Courses per year | 2-3 (spaced 4-6 months apart) |
| Monitoring | Telomere length at baseline, 3 months, and 6 months |
Extended Protocol (Advanced)
| Parameter | Recommendation |
|---|---|
| Dose | 10 mg subcutaneously, daily |
| Duration | 20 days |
| Timing | Evening (6-9 PM) |
| Courses per year | 2-3 |
| Monitoring | Telomere length, biological age markers, epigenetic clocks |
Administration
- Injection site: Abdominal subcutaneous tissue, rotating sides
- Reconstitution: Add bacteriostatic water to lyophilized powder (typically 2 mL per 10 mg vial)
- Storage: Reconstituted solution refrigerated (2-8 degrees C), use within 21 days
- Evening timing rationale: Epithalon supports melatonin synthesis via pineal gland stimulation. Evening administration aligns with the natural melatonin production cycle.
Monitoring: How to Know If It Is Working
Telomere testing is the only objective way to evaluate Epithalon’s primary mechanism. The monitoring schedule commonly used:
- Baseline telomere length before the first course (multiple testing methods exist — ensure you use the same method for all measurements)
- 3-month follow-up after completing the first course
- Pre-second-course measurement at 6 months
- Annual tracking to establish a trend line
The nuance matters here: single-point telomere measurements are noisy. Individual readings can vary by 5-10% depending on the method. What you want to see is a trend over 2-3 measurements — stabilization or lengthening rather than the expected age-related shortening of approximately 20-40 base pairs per year. Keep in mind that commercial telomere-length tests vary by method and laboratory, and a change in average blood-cell telomere length is not a validated measure of healthier ageing in an individual.
Combining Epithalon with Other Longevity Interventions
Epithalon is rarely used in isolation in longevity protocols. Common combinations:
Epithalon + NAD+ precursors (NMN/NR). These target different aging mechanisms — telomere lengthening (Epithalon) versus cellular energy and DNA repair (NAD+). The combination addresses two distinct hallmarks of aging. See the Epithalon vs NMN comparison for a detailed mechanistic analysis.
Epithalon + melatonin. Since Epithalon supports endogenous melatonin production via pineal stimulation, some clinicians reduce exogenous melatonin during Epithalon courses to avoid redundancy. Others maintain it. There is no data to guide this decision.
Epithalon + exercise and caloric restriction. Both exercise and caloric restriction independently support telomere maintenance. Combining these with Epithalon is a reasonable multi-mechanism approach.
Epithalon + rapamycin and mTOR inhibition. Some longevity protocols combine telomere support (Epithalon) with mTOR modulation (rapamycin). These target entirely different aging pathways and there is no expected pharmacological interaction.
Known and Theoretical Risks
Telomeres and cancer. Most human cancers depend on keeping their telomeres long, usually by reactivating telomerase, which is why telomerase inhibition has been explored as a cancer therapy (Shay & Wright, 2019). The finding that epithalon lengthened telomeres in breast cancer cell lines (Al-Dulaimi et al., 2025) does not show that it causes cancer in people. It does mean the question needs a real safety study, especially for anyone with a current or past cancer.
Unknown long-term safety. No published study has followed people using synthetic epithalon long enough, or in large enough numbers, to detect uncommon harms.
Product quality and immunogenicity. The FDA states that compounded epitalon may pose a risk of immunogenicity due to aggregation and peptide-related impurities. Research-grade products are not made or tested to pharmaceutical standards, and test purchases of other illegally sold injectable peptides found less active drug than labelled and contamination (Ashraf et al., 2024).
Injection-related harm. Home injections from multi-use vials carry a risk of local and, rarely, serious infection.
Contraindications:
- Active malignancy (theoretical telomerase concern warrants avoidance until more data exists)
- Pregnancy and lactation (no safety data)
- Active autoimmune disease (insufficient data on immune effects)
Regulatory Status
- United States (FDA): not an approved drug. On the FDA page Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026), epitalon is listed among substances formerly in 503A category 2 whose compounding nominations were withdrawn. The FDA states there that it “has not identified safety-related information regarding epitalon for the proposed route of administration”. Epitalon is not on the 503A bulks list or in category 1 of FDA’s May 2026 list.
- EU and Germany: not authorised by the European Medicines Agency or Germany’s BfArM. Labelling a product “research use only” does not make it an approved medicine or a product tested in people.
- Sport (WADA 2026 Prohibited List): prohibited at all times as a non-approved substance (S0).
When to Talk to a Physician
If healthy ageing is your goal, the interventions with the strongest human evidence are unglamorous: physical activity, blood pressure and lipid control, not smoking, sleep, and vaccinations. A physician can help you prioritise them based on your own risk profile, and can help you make an informed decision about whether a peptide like epithalon fits your situation.
If you have used epithalon, tell your doctor what you used, where it came from and for how long, especially if you have a personal or family history of cancer. Report any new lumps, unexplained weight loss, persistent fatigue or night sweats.
To take part in ageing research, search ClinicalTrials.gov or the EU Clinical Trials Register.
The Bottom Line
The usual community course is 5-10 mg subcutaneously daily for 10-20 days, two or three times a year. That dose comes from community practice; the published human studies used 10 mcg intramuscularly or 0.5 mg under the tongue. The mechanism — telomerase activation and telomere elongation — is shown in human cells, while the lifespan data in mice are mixed (no change in the average, longer survival in the longest-lived animals). The gap is the absence of controlled human trials, which means we are extrapolating from preclinical data and clinical observation rather than human RCTs, and telomere lengthening raises a legitimate cancer question that still needs a proper safety study. For people pursuing evidence-informed longevity optimization under physician supervision, Epithalon is one of the most mechanistically interesting peptides available, with the honest caveat that the human evidence is not yet definitive.
Back to Epithalon Overview | All Peptide Articles
References
- Jain A, et al. Epitalon and epithalamin: a narrative review of mechanistic, preclinical, and clinical evidence. Int J Mol Sci. 2026. PMID: 42884164.
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937682.
- Al-Dulaimi S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. PMID: 40908429. (Correction: PMID 41240216.)
- Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. PMID: 14501183.
- Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19830585.
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363.
- Shay JW, Wright WE. Telomeres and telomerase: three decades of progress. Nat Rev Genet. 2019. PMID: 30760854.
- Ashraf AR, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. J Med Internet Res. 2024. PMID: 39509151.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026); Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated 14 May 2026).
- World Anti-Doping Agency. The 2026 Prohibited List, valid 1 January 2026 (S0).
Disclaimer: This article is provided for informational and educational purposes only and is not a prescription or individual medical advice. Epithalon is not approved by the FDA, EMA or BfArM. It is not a substitute for individualized medical care. Consult a qualified physician before beginning any peptide protocol. Telomerase activation in the context of active malignancy is contraindicated.